42.48
-0.77 (-1.78%)
| Penutupan Terdahulu | 43.25 |
| Buka | 43.35 |
| Jumlah Dagangan | 337,071 |
| Purata Dagangan (3B) | 1,034,212 |
| Modal Pasaran | 3,426,699,008 |
| Harga / Jualan (P/S) | 1.54 |
| Harga / Buku (P/B) | 5.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| Margin Operasi (TTM) | -81,161.54% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -90.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.15% |
| Nisbah Semasa (MRQ) | 30.97 |
| Aliran Tunai Operasi (OCF TTM) | -81.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.18 M |
| Pulangan Atas Aset (ROA TTM) | -12.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | CG Oncology, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.17% |
| % Dimiliki oleh Institusi | 105.34% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 90.00 (Guggenheim, 111.86%) | Beli |
| Median | 68.50 (61.25%) | |
| Rendah | 47.00 (JP Morgan, 10.64%) | Beli |
| Purata | 67.38 (58.62%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 37.85 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 62.00 (45.95%) | Beli | 43.56 |
| RBC Capital | 17 Nov 2025 | 61.00 (43.60%) | Beli | 41.25 |
| Guggenheim | 08 Oct 2025 | 90.00 (111.86%) | Beli | 40.71 |
| JP Morgan | 26 Sep 2025 | 47.00 (10.64%) | Beli | 37.54 |
| Morgan Stanley | 17 Sep 2025 | 79.00 (85.97%) | Beli | 37.72 |
| HC Wainwright & Co. | 15 Sep 2025 | 75.00 (76.55%) | Beli | 34.60 |
| 08 Sep 2025 | 75.00 (76.55%) | Beli | 33.69 | |
| Cantor Fitzgerald | 08 Sep 2025 | 75.00 (76.55%) | Beli | 33.69 |
| Jones Trading | 08 Sep 2025 | 50.00 (17.70%) | Beli | 33.69 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2025 | Pengumuman | CG Oncology Announces New Board Member and Board Transition |
| 25 Nov 2025 | Pengumuman | CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting |
| 14 Nov 2025 | Pengumuman | CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 05 Sep 2025 | Pengumuman | CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |